This bill enacts a new provision in the Uniform Controlled Dangerous Substances Law, specifically adding Tianeptine to Schedule I. The new legal language specifies that unless Tianeptine is specifically exempted or included in a pharmaceutical product approved by the United States Food and Drug Administration, any material, compound, mixture, or preparation containing Tianeptine, including its salts, isomers, or salts of isomers, will be classified under Schedule I.

The addition of Tianeptine to Schedule I indicates that it is considered to have a high potential for abuse and is not accepted for medical use in the United States, aligning with the classification of other controlled substances. This legislative action aims to regulate the use and distribution of Tianeptine in Louisiana, reflecting growing concerns about its safety and potential for misuse.